psilocybin
LSD treatment for Alzheimer’s patients proves safe in recent trial
December 19, 2019Business Services Alzheimer's, FDA, LSD, Magic mushrooms, psilocybin
The results of a Phase 1 clinical trial shows that Lysergic Acid Diethylamide (LSD) can be microdosed safely, and potentially …
FDA fast-tracks psilocybin treatment for major depressive disorder
November 25, 2019Sales and Marketing Controlled Substance Act, FDA, breakthrough therapy, major depressive disorder, psilocybin
The FDA has granted a Breakthrough Therapy designation to the Usona Institute for its trial use of psilocybin in the …
Johns Hopkins researchers to study psilocybin as a treatment for anorexia in Phase 1 trial
August 28, 2019Research and Development Johns Hopkins, Magic mushrooms, anorexia, mushrooms, pharma, psilocybin
Scientists at Johns Hopkins University are exploring psilocybin as a potential treatment for chronic anorexia nervosa. Researchers at Johns Hopkins …
Illegal psilocybin shows promise in treatment of depression
December 1, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Johns Hopkins, Magic mushrooms, psilocybin
A double-blind study of psilocybin, the hallucinogenic drug chemical found in ‘magic mushrooms’, has been found to have substantial mental …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
